Protherics was formed in September 1999 from the merger of Proteus International Plc and Therapeutic Antibodies Inc. Complementary product portfolios and management teams created the foundation for a strong and focused business.
In 2001, we launched our first FDA-approved product CroFab™, the first new rattlesnake antivenom on the US market in fifty years and this was closely followed by the US launch of DigiFab®, a treatment for the toxic effects of overdosage with the heart drug Digoxin. Two FDA approvals within twelve months demonstrate Protherics' ability to deliver marketable products from our R&D pipeline.
Protherics continues to make strong progress. In June 2003 we acquired Enact Pharma PLC, an OFEX traded company, which further strengthened our clinical pipeline. We announced at our interim results for the six months ended 30th September 2003, that Protherics' existing operations were profitable for the second consecutive half year. Investment continues in our manufacturing capability and R & D pipeline, the future of our business.
On 4th December 2008 Protherics was acquired by BTG plc